Lv23
180 积分 2025-08-28 加入
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
1天前
待确认
Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment
3个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
3个月前
已完结
皖公网安备34019202002308
